Statins as Repurposed Drugs in Gynecological Cancer: A Review

• Published in: International journal of molecular sciences Vol. 23; no. 22; p. 13937
• Main Authors: Wang, Kai-Hung, Liu, Chin-Hung, Ding, Dah-Ching
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11.11.2022; MDPI
• Subjects: Apoptosis; Cardiovascular Diseases - drug therapy; Cervical cancer; Endometrial cancer; Gynecological cancer; Human papillomavirus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Mortality; Neoplasms - drug therapy; Ovarian cancer; Review; Statins; Tumor Microenvironment; Womens health; endometrial cancer; repurposed drugs; ovarian cancer; cervical cancer; statins; gynecological cancer
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232213937

Discovering new drugs is an expensive and time-consuming process, including target identification, bioavailability, pharmacokinetic (PK) tests, pharmacodynamic (PD) tests, toxicity profiles, recommended dosage test, and observation of the side effects, etc. Repurposed drugs could bypass some steps, starting from phase II trials, and shorten the processes. Statins, also known as HMG-CoA inhibitors (HMGCR), are commonly used to manage and prevent various cardiovascular diseases and have been shown to improve the morbidity and mortality of patients. In addition to the inhibitory effects on the production of cholesterol, the beneficial effects of statins on the prognosis and risk of various cancers are also shown. Statins not only inhibited cell proliferation, metastasis, and chemoresistance but affected the tumor microenvironment (TME). Thus, statins have great potential to be repurposed in oncology. Hence, we review the meta-analysis, cohort, and case-control studies of statins in gynecological cancers, and elucidate how statins regulate cell proliferation, apoptosis, tumor growth, and metastasis. Although the results in gynecological cancers remain controversial and the effects of different statins in different histotypes of gynecological cancers and TME are needed to elucidate further, statins are excellent candidates and worthy of being repurposed drugs in treating gynecological cancers.